an update on the use of navtemadlin in myelofibrosis
Published 1 year ago • 190 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
10:49
mayo clinic rochester
-
6:24
indiko biochemistry analyzer demonstration
-
2:03
myeloproliferative neoplasms: what’s happening inside the body
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:55
current and emerging treatments for mf: an update from ash 2023
-
3:19
finding novel targets for myelofibrosis from animal models
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
1:52
aml19 update: improvement in os in patients with npm1-mutated aml treated with flag-ida-go
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
3:31
post-induction undetectable mrd ameliorates the high risk determined by fish among ndmm
-
5:18
upfront treatment in transplant candidates
-
1:30
a phase i trial investigating a novel oral flt3 inhibitor, bmf-500, in flt3-mutant aml
-
1:37
mrd in myeloma
-
1:52
cytoreductive therapy for patients with pv
-
1:53
the future of multiple myeloma treatment